FDA 483 OBSERVATION · #52 OF 1,923 MOST-CITED
Design changes - Lack of or Inadequate Procedures
FDA cited this observation 466 times across 418 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
A device firm lacked adequate procedures for the identification, documentation, validation (or verification), review, and approval of design changes before their implementation.
Why FDA writes it — A change to a validated design can reintroduce risk the original design controls were meant to remove. Without a controlled design-change process, changes are made without assessing their effect on safety and performance — a direct path to a defective device reaching the market.
- Establish procedures for the identification, documentation, validation or verification, review, and approval of design changes before implementation.
- Assess each change for its effect on the device’s safety, performance, and its risk analysis (ISO 14971).
- Verify or validate the change as appropriate to its impact, and update the design history file and risk file.
- Approve changes through the defined authority before they are implemented.
- Design changes implemented informally by engineering without routing through design control.
- Change impact assessed narrowly, missing effects on risk, verification, or downstream requirements.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.7× the rate of the average FDA-cited firm (12.9% vs 7.8%), across 418 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for design change have not been adequately established.
Procedures for design change have not been established.
Procedures for design change have not been adequately established.
Procedures for design change have not been adequately established.
Procedures for design change have not been adequately established.
Procedures for design change have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →